Posts Tagged: "Hassan"

California Ahead of Federal Government in Cybersecurity for the Internet of Things

The bill would create a new title within California Civil Code named Security of Connected Devices. The first part of this title would require a manufacturer of a connected device, defined as any object capable of connecting to the Internet and assigned either an Internet protocol address or a Bluetooth address, to equip the device with reasonable security features appropriate to the nature and function of the device, appropriate to the information it may collect or transmit and designed to protect both the device and the information it contains from unauthorized access.

Senate Commerce Committee Holds FCC Oversight Hearing to Discuss Net Neutrality and Rural Broadband Deployment

Last week the Senate Committee on Commerce, Science, and Transportation held a hearing to conduct oversight of the Federal Communications Commission (FCC). Although there was the typical overblown bickering over the FCC’s action on net neutrality rules taken in recent months under FCC Chairman Ajit Pai that one might expect, much of the day’s hearing focused on the poor quality of current broadband coverage maps employed by the FCC in distributing subsidies as well as the need to improve broadband deployment to reach millions of Americans living in rural communities.

St. Regis Mohawks, BIO send letters to Senate Judiciary slamming the unfair playing field of IPRs at PTAB

On Thursday, October 12th, a pair of letters addressed to the bipartisan leadership of the Senate Judiciary Committee were delivered in an attempt to inform Senators on that committee of various issues in play regarding the recent patent deal between multinational pharmaceutical firm Allergan and the sovereign St. Regis Mohawk Tribe. The two groups sending the letters represent stakeholders in the U.S. patent system coming from very different backgrounds who realize that there are fundamental flaws in the system created by inter partes review (IPR) proceedings which are carried out at the Patent Trial and Appeal Board (PTAB).

Efficient infringer lobby achieves bipartisan effort to abrogate Native American tribal sovereignty

The patent deal with the St. Regis tribe doesn’t shield the patents from validity challenges coming from a Hatch-Waxman trial recently concluded in Texas federal court. “To be clear, if the District Court ruling is adverse to Allergan’s patent position, and there is an FDA approval of a generic version of RESTASIS®, that product could enter the market many years in advance of the listed patent expiry dates,” Allergan’s note reads. The drugmaker further argues that the IPR process in force at the PTAB undermines the 33-year-old Hatch-Waxman statutory regime regarding validity challenges to pharmaceutical patents, is subject to changes to validity proceedings implemented within the executive branch which are not impartial, and creates an unfair burden on innovators by opening patents to challenge proceedings which are often inconsistent before both the PTAB and the Court of Appeals for the Federal Circuit, the court to which PTAB decisions can be appealed.